JP2022540917A5 - - Google Patents
Info
- Publication number
- JP2022540917A5 JP2022540917A5 JP2022502537A JP2022502537A JP2022540917A5 JP 2022540917 A5 JP2022540917 A5 JP 2022540917A5 JP 2022502537 A JP2022502537 A JP 2022502537A JP 2022502537 A JP2022502537 A JP 2022502537A JP 2022540917 A5 JP2022540917 A5 JP 2022540917A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- gaboxadol
- pharmaceutically acceptable
- acceptable salt
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874152P | 2019-07-15 | 2019-07-15 | |
| US62/874,152 | 2019-07-15 | ||
| PCT/US2020/042044 WO2021011597A1 (en) | 2019-07-15 | 2020-07-15 | Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022540917A JP2022540917A (ja) | 2022-09-20 |
| JP2022540917A5 true JP2022540917A5 (enExample) | 2023-07-26 |
Family
ID=74211193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502537A Pending JP2022540917A (ja) | 2019-07-15 | 2020-07-15 | 治療的処置のためのガボキサドール含有医薬製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20210015760A1 (enExample) |
| EP (1) | EP3982937A4 (enExample) |
| JP (1) | JP2022540917A (enExample) |
| KR (1) | KR20220035195A (enExample) |
| CN (2) | CN118141810A (enExample) |
| AU (1) | AU2020313930A1 (enExample) |
| CA (1) | CA3146737A1 (enExample) |
| IL (1) | IL289657A (enExample) |
| MX (1) | MX2022000663A (enExample) |
| WO (1) | WO2021011597A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3795156A1 (en) * | 2014-06-06 | 2021-03-24 | Ovid Therapeutics, Inc. | Pharmaceutical composition for treating angelman syndrome |
| EP3154979B1 (en) * | 2014-06-12 | 2018-03-07 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
| US20170348232A1 (en) * | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| KR20230050474A (ko) * | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| EP3528807A4 (en) * | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN |
-
2020
- 2020-07-15 EP EP20840941.7A patent/EP3982937A4/en active Pending
- 2020-07-15 WO PCT/US2020/042044 patent/WO2021011597A1/en not_active Ceased
- 2020-07-15 MX MX2022000663A patent/MX2022000663A/es unknown
- 2020-07-15 AU AU2020313930A patent/AU2020313930A1/en not_active Abandoned
- 2020-07-15 US US16/929,345 patent/US20210015760A1/en not_active Abandoned
- 2020-07-15 CN CN202410172907.XA patent/CN118141810A/zh active Pending
- 2020-07-15 JP JP2022502537A patent/JP2022540917A/ja active Pending
- 2020-07-15 KR KR1020227005115A patent/KR20220035195A/ko not_active Ceased
- 2020-07-15 CN CN202080051393.2A patent/CN114173765A/zh active Pending
- 2020-07-15 CA CA3146737A patent/CA3146737A1/en active Pending
-
2021
- 2021-10-21 US US17/507,369 patent/US20220040120A1/en not_active Abandoned
-
2022
- 2022-01-06 IL IL289657A patent/IL289657A/en unknown
-
2024
- 2024-04-09 US US18/630,105 patent/US20240252447A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU695865B2 (en) | Novel pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound | |
| JP7534354B2 (ja) | 朝の無動状態を治療するための拍動性薬物送達系 | |
| CA2691991C (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors | |
| JP2024074963A5 (enExample) | ||
| JP2021519288A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| KR100651110B1 (ko) | 테르비나핀을 포함하는 제약학적 조성물 및 그의 용도 | |
| KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
| CA2618212C (fr) | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique | |
| AU2014299447B2 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
| RU2642962C9 (ru) | Терапия болезни паркинсона с применением комбинации с фиксированными дозами | |
| RU2261098C2 (ru) | Перорально распадающаяся композиция, содержащая миртазапин | |
| JP2025509278A5 (enExample) | ||
| JP2022177119A5 (enExample) | ||
| KR101697773B1 (ko) | 독소필린을 포함하는 변형 방출 조성물 | |
| JP2024523123A (ja) | 去勢抵抗性前立腺がんの治療薬の調製におけるスタキオースの使用 | |
| JP2009522294A5 (enExample) | ||
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| JP2024084670A5 (enExample) | ||
| JP2025522146A5 (enExample) | ||
| JP2023549605A5 (enExample) | ||
| US20230028539A1 (en) | Pharmaceutical composition, complementary kit and application thereof | |
| JP2023507764A5 (enExample) | ||
| CN114557992B (zh) | 一种复方药物组合物在制备治疗间质性肺炎药物中的应用 | |
| US12303604B1 (en) | Pharmaceutical formulations comprising naltrexone and/or bupropion |